Company profile
Neurobiological Technologies, Inc.
OTC: NTII · Healthcare · Biotechnology
#519 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ —GM —SS 38
v0.1 · 5/100 weight · pillars only
↑ return on equity, return on assets · ↓ market scale, workforce scale
Methodology →Revenue TTM
$28.8M
Rev growth YoY (TTM)
+99.7%
Net income (FY)
$3.1M
Employees
4
as of 2026-08-30
Market cap
$2.7k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$26.4M$26.4M2008
Net income$3.1M$3.1M2008
Operating income$3.5M$3.5M2008
Total assets$2.6M$2.6M2009
Liabilities$1.0M$1.0M2009
Equity$1.5M$1.5M2009
Revenue trend
FY2001 – FY2008 · USD
FY01
FY02
FY03
FY04
FY05
FY06
FY07
FY08
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Neurobiological Technologies, Inc.’s revenue?
Neurobiological Technologies, Inc. booked $26.4M in FY2008 revenue, growing 79% year over year — faster than most Healthcare companies we track, at a 11.9% net margin.
Peers · Healthcare
Cue Biopharma, Inc.50DINNOCAN PHARMA Corp59CCelularity Inc.31DSynovics Pharmaceuticals, Inc.——Biocept, Inc.——RBC Life Sciences, Inc.——Neighbors
Alameda →Key facts
CEOJohn B. Stuppin
SectorHealthcare
IndustryBiotechnology
HeadquartersEmeryVille, CA
ExchangeOTC: NTII
Employees4
IPO date1994-10-31
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.